Purchase this article with an account.
Shigeru Kinoshita; Divergence between Medical Breakthroughs in Corneal Endothelial Treatment and Applied Clinical Practice. Invest. Ophthalmol. Vis. Sci. 201657(12):.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Presentation Description :
Understanding the biological and immunological characteristics of human corneal endothelial cells (CECs) is an essential key to the establishment of new strategies for treating bullous keratopathy caused by corneal endothelial diseases such as Fuchs Endothelial Corneal Dystrophy. In fact, we have been developing a novel ‘cell-injection therapy’ involving the injection of cultured human CECs into the anterior chamber. Our findings in 18 clinical research cases have shown this approach to be extremely promising. However, in order to apply this novel approach to actual clinical practice, several key safety issues must be addressed and assured from the aspect of regulatory science.It is our great hope that ophthalmology-related translational research, such as that described above, will soon receive official governmental approval based upon the accumulated data of safety and efficacy aspects associated with the procedures.
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.
This PDF is available to Subscribers Only